Literature DB >> 6689652

Colipase and lipase secretion in childhood-onset pancreatic insufficiency. Delineation of patients with steatorrhea secondary to relative colipase deficiency.

K J Gaskin, P R Durie, L Lee, R Hill, G G Forstner.   

Abstract

Pancreatic lipase and colipase secretion was assessed in 64 patients with pancreatic disease, 24 of whom had steatorrhea, and in 14 control subjects. A wide range of lipase and colipase secretion was seen in patients both with and without steatorrhea. Considerable loss of pancreatic lipase and colipase secretion had to occur before steatorrhea developed, as the highest hourly secretion of lipase and colipase in this group of patients was less than 4% and less than 2%, respectively, of the lowest values recorded in normal subjects. Colipase and lipase outputs were very strongly correlated (r = 0.96) throughout the range of pancreatic function. Lipase was always unsaturated with respect to colipase, but in only a limited number of patients with relatively low pancreatic secretion was the degree of unsaturation greater than 2 standard deviations below the mean. The importance of low saturation or low colipase secretion was evident in a group of 11 patients with a narrow range of lipase secretion in a transitional zone between secretion rates associated with steatorrhea and with normal fat excretion. In this group, 7 patients were identified in whom colipase deficiency appeared to be the sole cause of steatorrhea. The correlation of colipase secretion with the level of fecal fat excretion was highly significant (p less than 0.001) and indicated that fat digestion and subsequent fat absorption depended on colipase secretion up to at least a level of 25% fecal fat excretion. Nonpancreatic factors could well govern the extent of fat absorption above this level, as colipase secretory values in this range were uniformly low.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6689652

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  19 in total

Review 1.  Cystic fibrosis. 6. Gastrointestinal and nutritional aspects.

Authors:  H Kopelman
Journal:  Thorax       Date:  1991-04       Impact factor: 9.139

Review 2.  Pathophysiology of the exocrine pancreas in cystic fibrosis.

Authors:  P R Durie; G G Forstner
Journal:  J R Soc Med       Date:  1989       Impact factor: 5.344

Review 3.  A rational approach to the nutritional care of patients with cystic fibrosis.

Authors:  P R Durie; P B Pencharz
Journal:  J R Soc Med       Date:  1989       Impact factor: 5.344

4.  Isolated lipase and colipase deficiency in two brothers.

Authors:  M Ligumsky; E Granot; D Branski; H Stankiewicz; R Goldstein
Journal:  Gut       Date:  1990-12       Impact factor: 23.059

Review 5.  Uses and abuses of enzyme therapy in cystic fibrosis.

Authors:  P Durie; D Kalnins; L Ellis
Journal:  J R Soc Med       Date:  1998       Impact factor: 5.344

Review 6.  Gastrointestinal tract and nutrition in cystic fibrosis: pathophysiology.

Authors:  J A Dodge
Journal:  J R Soc Med       Date:  1986       Impact factor: 5.344

Review 7.  Cystic fibrosis--a gastroenterological cornucopia.

Authors:  P L Zentler-Munro
Journal:  Gut       Date:  1987-11       Impact factor: 23.059

8.  Serum immunoreactive cationic trypsinogen: a useful indicator of severe exocrine dysfunction in the paediatric patient without cystic fibrosis.

Authors:  D J Moore; G G Forstner; C Largman; G J Cleghorn; S S Wong; P R Durie
Journal:  Gut       Date:  1986-11       Impact factor: 23.059

9.  Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas.

Authors:  N Ahmed; M Corey; G Forstner; J Zielenski; L-C Tsui; L Ellis; E Tullis; P Durie
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

10.  Delayed release pancrelipase for treatment of pancreatic exocrine insufficiency associated with chronic pancreatitis.

Authors:  Devi Mukkai Krishnamurty; Atoosa Rabiee; Sanjay B Jagannath; Dana K Andersen
Journal:  Ther Clin Risk Manag       Date:  2009-07-12       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.